Clinical Trial Update: Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes evaluating the combination of cladribine and rituximab for hairy cell leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Leustatin (cladribine)
• Rituxan (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 2 | Status: RECRUITING